Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Ikaria and Aptalis, Private Equity Investors Get Creative To Cash Out

This article was originally published in The Pink Sheet Daily

Executive Summary

Ikaria shareholders sold the commercial side of that critical care business, but retained a stake in the off-loaded assets. While gastrointestinal and cystic fibrosis company Aptalis turns to an IPO instead of an acquisition.

Advertisement

Related Content

Forest Builds On Saunders’ Strategy With $2.9B Aptalis Buy
In Split, Ikaria Looks For Products, While New R&D Play Preps For IPO
Ikaria’s Hybrid Business Model Taps Big Pharma Trends
Aptalis’ Ultresa And Viokace Join Crowded Marketplace Of Pancreatic Enzyme Products

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel